



Press release from Emotra AB (publ)  
Göteborg, March 24, 2014

## Kick-off meeting in Rome on April 14–15

**Emotra is proud to announce that the kick-off meeting of the Company's multi-centre study will take place in Rome, Italy, on April 14–15, 2014. This meeting marks the actual start of the study, and will also include a training programme for the clinics.**

The meeting is a joint arrangement between Emotra and The European Psychiatric Association's Section on Suicidology and Suicide Prevention. 26 professionals from 16 clinics will participate in this meeting, which will also include a training programme for the clinics. The trials are planned to take place during the coming two years. Emotra's product has now received CE marking, and we will start testing patients as soon as the local ethical committees have given the green light.

So far, 17 clinics have signed agreements to participate in the evaluation of Emotra's method, EDOR. Another clinic or two are likely to join the study in the near future, and after next summer we may also add a small number of clinics selected among those that have shown interest in participating in the study.

Emotra has entered a dynamic phase with an increasing number of clinical partners. In this phase, the Company is being run with a skeleton crew and as cost-effectively as possible in order not to jeopardise its long-term financial health. Once Emotra's method has received sufficiently strong scientific backing from the clinics evaluating EDOR, we will initiate a launch of the method in Europe.

**For further information, please contact:**

*Claes Holmberg, CEO*  
*Telephone: +46 708 25 45 47*  
*E-mail: [claes@emotra.se](mailto:claes@emotra.se)*

*Lars-Håkan Thorell, Head of Research*  
*Telephone: +46 733 95 31 20*  
*E-mail: [lars@emotra.se](mailto:lars@emotra.se)*

---

*Emotra AB is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.*